Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 18, Issue 9, 2000, Pages 1812-1823

  Waters, Justin S ^a   Webb, Andrew ^a   Cunningham, David ^a   Clarke, Paul A ^a   Raynaud, Florence ^a   Di Stefano, Francesca ^a   Cotter, Finbarr E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; OBLIMERSEN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER GENETICS; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; FEMALE; FEVER; HUMAN; HUMAN CELL; HYPOTENSION; LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0034015672     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.9.1812     Document Type: Article

References (38)

1. Hockenbery D, Nunez G, Milliman C, et al: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336, 1990
2. Miyashita T, Reed JC: Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52:5407-5411, 1992
3. McDonnell TJ, Nunez G, Platt FM, et al: Deregulated Bcl-2-immunoglobulin transgene expands a resting but responsive immunoglobulin M and D-expressing B-cell population. Mol Cell Biol 10: 1901-1907, 1990
4. McDonnell TJ, Korsmeyer SJ: Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 349:254-256, 1991
5. Hermine O, Haioun C, Lepage E, et al: Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma: Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 87:265-272, 1996
6. Hill ME, MacLennan KA, Cunningham DC, et al: Prognostic significance of BCL-2 expression and Bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation study. Blood 88:1046-1051, 1996
7. Gascoyne RD, Adomat SA, Krajewski S, et al: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:244-251, 1997
8. Kitada S, Miyashita T, Tanaka S, et al: Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Res Dev 3:157-169, 1993
9. Kitada S, Takayatna S, de Riel K, et al: Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 4:71-79, 1994
10. Cotter FE, Johnson P, Hall P, et al: Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9:3049-3055, 1994
11. Webb A, Cunningham D, Cotter F, et al: Bcl-2 antisense therapy in patients with non Hodgkin's lymphoma. Lancet 349:1137-1141, 1997
12. Raynaud FI, Orr RM, Goddard PM, et al: Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther 281:420-428, 1997
13. Jansen B, Wacheck V, Heere-Ress E, et al: A phase I-II study with dacarbazine and BCL-2 antisense oligonucleotide G3139 (GENTA) as a chemosensitizer in patients with advanced malignant melanoma. Proc Am Soc Clin Oncol 18:531a, 1999 (abstr 2049)
14. Morris MJ, Tong W, Osman I, et al: A phase I/IIa trial of bcl-2 antisense (G3139) treatment by 14-day continuous infusion (CI) for patients with androgen-independent prostate cancer or other advanced solid tumor malignancies. Proc Am Soc Clin Oncol 18:323a, 1999 (abstr 1243)
15. Nemunaitis J, Eckhardt G, Dorr A, et al: Phase I evaluation of CGP 6412SA, an antisense inhibitor of protein kinase C-alpha (PKCα), in patients with refractory cancer. Proc Am Soc Clin Oncol 16:246a, 1997 (abstr 870)
16. Jansen B, Schlagbauer-Wadl H, Brown BD, et al: Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4:232-234, 1998
17. O'Dwyer PJ, Stevenson JP, Gallagher M, et al: Phase I/pharmacokinetic/pharmacodynamic trial of Raf-1 antisense ODN (ISIS 5132, CGP 69846A). Proc Am Soc Clin Oncol 17:210a, 1998 (abstr 810)
18. Yacyshyn BR, Bowen Y-MB, Jewell L, et al: A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 114:1133-1142, 1998
19. Wooldridge JE, Ballas Z, Krieg AM, et al: Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 89:2994-2998, 1997
20. Ballas ZK, Rasmussen WL., Krieg AM: Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157:1840-1845, 1996
21. Jakob T, Walker PS, Krieg AM, et al: Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 161:3042-3049, 1998
22. Sikic BI, Yuen AR, Advani R, et al: Antisense oligonucleotide therapy targeted to protein kinase C-alpha (ISIS 3521/CGP 64128A) by 21 day infusion: Results of the phase I trial and activity in ovarian carcinomas. Proc Am Soc Clin Oncol 17:429a, 1998 (abstr 1654)
23. Holmlund J, Nemunaitis J, Schiller J, et al: Phase I trial of c-raf antisense oligonucleotide ISIS 5132 (CGP 69846A) by 21-day continuous intravenous infusion (CIV) in patients with advanced cancer. Proc Am Soc Clin Oncol 17:210a, 1998 (abstr 811)
24. Glover JM, Leeds JM, Mant TG, et al: Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp Ther 282: 1173-1180, 1997
25. Bishop MR, Iversen PL, Bayever E, et al: Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol 14:1320-1326, 1996
26. Shaw DR, Rustagi PK, Kandimalla ER, et al: Effects of synthetic oligonucleotides on human complement and coagulation. Biochem Pharmacol 53:1123-1132, 1997
27. Hockenbery DM, Zutter M, Hickey W, et al: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A 88:6961-6965, 1991
28. Veis DJ, Sorenson CM, Shutter JR, et al: Bcl-2 deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75:229-240, 1993
29. Kamada S, Shimono A, Shinto Y, et al: Bcl-2 deficiency in mice leads to pleiotropic abnormalities: Accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. Cancer Res 55:354-359, 1995
30. Park JR, Bernstein ID, Hockenbery DM: Primitive human haematopoietic precursors express bcl-x but not bcl-2. Blood 86:868-876, 1995
31. Motoyama N, Wang F, Roth KA, et al: Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 267:1506-1510, 1995
32. Phillips JA, Craig SJ, Bayley D, et al: Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (GCP69846A) after intravenous and subcutaneous administration. Biochem Pharmacol 54:657-668, 1997
33. Zhang RW, Yan JM, Shahinian H, et al: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (Gem-91) in HIV infected subjects. Clin Pharmacol Ther 58:44-53, 1995
34. Geary RS, Leeds JM, Henry SP, et al: Antisense oligonucleotides for the treatment of cancer: I. Pharmacokinetic properties of phosphorothioate oligonucleotides. Anticancer Drug Design 12:383-393, 1997
35. Wong F, Bally M, Klasa R: Antisense oligonucleotides to bcl-2 with low dose cyclophosphamide cures SCID/Rag-2 mice with a human B cell lymphoma. Proc Am Assoc Cancer Res 40:20, 1999 (abstr)
36. Yang D, Ling Y, Almazan M, et al: Tumour regression of human breast carcinomas by combination therapy of anti-Bcl-2 antisense oligonucleotide and chemotherapeutic drugs. Proc Am Assoc Cancer Res 40:729, 1999 (abstr)
37. Zangemeister-Wittke U, Schenker T, Luedke GH, et al: Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 78:1035-1042, 1998
38. Tolcher A, Miyake H, Cleave M: Downregulation of Bcl-2 expression by antisense oligonucleotide treatment enhances mitoxantrone cytotoxicity in the androgen-dependent Shionogi tumour model. Proc Am Assoc Cancer Res 40:484, 1999 (abstr)